Antibiotic-Impregnated Catheter (AIC) Overview

• Antibiotic-impregnated catheters (AICs) are silicone-based devices integrated with agents like rifampin and clindamycin to reduce implant-associated infections and inflammation.
• Research employs methodologies such as controlled antibiotic elution kinetics, 16S rRNA sequencing for microbiome profiling, and MRI for assessing neural tissue response.
• Findings indicate that AICs modulate the peri-catheter microbiome and reduce chronic macrophage activation, potentially lowering shunt obstruction and device failure.

An antibiotic-impregnated catheter (AIC) is a medical device composed of a silicone sheath in which bacteriostatic or bactericidal agents, such as rifampin and clindamycin, are integrated into the polymer matrix during manufacturing. AICs are designed to reduce implant-associated infections and peri-catheter inflammation. In the context of neurosurgery and shunt-dependent hydrocephalus, AICs are compared against plain silicone catheters (PSC) for their influence on both local microbiome composition and chronic neuroimmune sequelae, particularly glial scarring and macrophage activation, which are closely linked to shunt obstruction and device failure (Zhu et al., 7 Feb 2026).

1. Composition and Preparation

Commercial AICs, such as Bactiseal (Integra Lifesciences), employ proprietary impregnation methods to integrate rifampin and clindamycin throughout a silicone matrix. In experimental protocols, AIC fragments are hand-cut to dimensions of approximately 1.00 mm × 1.00 mm × 0.65 mm and sterilized using ethylene oxide gas. The antibiotic elution profile, as established in previous work on Bactiseal catheters (Bayston & Lambert, J Neurosurg 1997), exhibits first-order release kinetics, typically modeled as $C(t) = C_0\,e^{-kt}$, where $C_0$ denotes the initial surface concentration and $k$ an empirically determined release constant (not measured in the referenced preclinical work). Residual antimicrobials persist for up to 56 days post-implantation.

2. Experimental Deployment and Surgical Methods

AIC evaluation in murine models entails both microbiome and MRI assessment cohorts. For microbiome analysis, mice receive simultaneous intracranial (parietal burr hole, intraparenchymal placement) and peritoneal (adjacent to cecum) implantation under ketamine/xylazine/ethanol anesthesia (“Xylanest”). Implants are secured using 6-0 suture closure. The acute (POD 7) and chronic (POD 28) post-operative intervals structure tissue harvest. MRI analysis is performed in a 2-mouse cohort at weeks 1, 4, 8, and 16 post-implantation, focusing exclusively on brain implants.

3. Microbiome Profiling and Analysis

Microbial detection employs 16S rRNA V4-region amplicon sequencing (Illumina MiSeq, >10,000 post-QC reads per sample). Data are processed via QIIME 2 (v2024.5), with host read removal (Kraken2), denoising (DADA2; trimming first 10 bp, truncating at 180 bp), closed-reference OTU picking at 99% identity (VSEARCH, SILVA 138), and taxonomic assignment (Naïve Bayes, SILVA 99%). Samples with <100 OTUs are excluded. Diversity metrics include the Shannon index $H' = -\sum p_i \ln p_i$, and the Chao1 richness estimator.

AIC-implanted brain samples reveal no statistically significant change in Shannon H′ or Chao1 richness relative to controls (p > 0.2, Wilcoxon). However, beta diversity (weighted UniFrac distances) demonstrates distinct clustering for AIC samples (PERMANOVA p ≈ 0.001). Differential abundance analysis using LEfSe uncovers enrichment of immune-regulatory taxa—specifically Akkermansiaceae (notably genus Akkermansia), Parabacteroides, and unclassified Clostridiales. Log₂-fold changes from day 28 versus day 7 indicate Akkermansia (+1.8), Bacteroides (+1.2), and Turicibacter (+0.9) increase.

4. Functional Metagenomics and Pathway Inference

Inferred functional pathway enrichment is performed using PICRUSt2 in stratified mode. Analysis focuses on short-chain fatty acid (SCFA) biosynthesis and lipopolysaccharide (LPS) biosynthesis pathways. SCFA biosynthetic potential is markedly elevated in AIC versus both unaltered control (Cliff’s δ = +0.76, p = 0.0524) and PSC (δ = –0.733, p = 0.0513), values exceeding the |δ| > 0.6 threshold for large effect size. LPS biosynthetic potential is moderately reduced in AIC versus PSC (δ = –0.44, p ≈ 0.31). This functional profile corresponds with microbial community shifts toward SCFA-producing and immune-regulatory taxa.

5. MRI-Based Outcomes: Edema, Glial Scar, and Macrophage Activation

Longitudinal MRI (T2-weighted, FLAIR, multi-echo SWI) quantifies spatiotemporal dynamics of edema and glial scarring. Implant volumes remain stable for AIC (mean implant ROI: 0.92 mm³ across all time points). Edema resolves from 0.45 mm³ (week 1) to ≈0.02 mm³ (weeks 8 and 16). Glial scar expands between week 1 (0.05 mm³) and week 4 (0.38 mm³), then stabilizes. No significant differences in gross edema or glial scar volumes are observed between AIC and PSC.

Quantitative susceptibility mapping (R₂) reveals lower macrophage-associated iron signal in AIC versus PSC, with mean R₂ in scar ROI lower by ~5–12 s⁻¹ at weeks 4–16 (AIC: 55–60 s⁻¹; PSC: 62–72 s⁻¹; contralateral tissue stable at ~12 s⁻¹). R₂* is computed as $R_2^* = -d \ln S(\mathrm{TE})/d\,\mathrm{TE}$ via linear fit over six echo times. Reduced R₂* in AIC-implanted animals indicates diminished chronic macrophage activity within the peri-catheter glial scar.

6. Interpretation and Implications for Device Performance

AICs selectively shift the peri-catheter brain microbiome toward SCFA-producing and immune-regulatory taxa while reducing enrichment of pro-inflammatory, LPS-associated taxa detected with PSC. Functional inference supports this, with strong positive shifts in SCFA potential (δ ≈ +0.76) and moderate negative shifts in LPS biosynthesis potential (δ ≈ –0.44) relative to PSC. Although neither gross edema nor scar volumes differ notably between groups, lower R₂* values suggest reduced macrophage-driven neuroinflammation in AIC settings.

These findings imply that antibiotic impregnation modulates the local peri-catheter niche at the interface between the implant and neural tissue, promoting anti-inflammatory microbiota and dampening neuroimmune activation. A plausible implication is that through modulation of the low-biomass microbial environment, AICs may attenuate chronic glial scarring—a principal risk factor for proximal shunt obstruction and device failure. The results support the hypothesis that catheter biomaterial and surface chemistry orchestrate critical microbial–immune interactions in the brain, suggesting that advances in antimicrobial coatings or targeted ecological stabilization strategies represent promising avenues for reducing shunt failure due to obstruction (Zhu et al., 7 Feb 2026).